Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 11, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metrics disclosed relate to the share buyback transaction:
- Shares Purchased: 1,446,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,564 pence per share; lowest price paid was 1,548 pence per share.
- Treasury Holdings (Settled): 493,019,912 shares (9.19% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,367,912 shares (10.21% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,873,152,704 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the October 11 transaction. The filing text does not provide comparative financial data or material changes regarding operational performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share repurchases.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (493,019,912 settled) against the Company's latest capital structure.
- Confirm the percentage of total voting rights held in Treasury (10.21% including unsettled shares) for disclosure threshold calculations.
- Check the total issued share capital excluding treasury shares (4,873,152,704) for accurate EPS or ownership percentage calculations.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.